Predictors and risk model development for menopausal age in fragile X premutation carriers

Genetics in Medicine

Volumn 13, Issue 7, 2011, Pages 643-650

  Spath, Marian A ^a,b   Feuth, Ton B ^b   Smits, Arie P T ^b   Yntema, Helger G ^b   Braat, Didi D M ^a   Thomas, Chris M G ^a   Van Kessel, Ad Geurts ^b   Sherman, Stephanie L ^c   Allen, Emily G ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Human Genetics ^*  (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FMR1 premutation; fragile X associated primary ovarian insufficiency (FXPOI); menopause; prediction

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FEMALE; FRAGILE X SYNDROME; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MUTATIONAL ANALYSIS; POPULATION RESEARCH; PREMATURE OVARIAN FAILURE; RISK ASSESSMENT; RISK FACTOR; TRINUCLEOTIDE REPEAT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BASE SEQUENCE; COHORT STUDIES; FAMILY HEALTH; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MENOPAUSE; MIDDLE AGED; MUTATION; PRIMARY OVARIAN INSUFFICIENCY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; TRINUCLEOTIDE REPEAT EXPANSION; YOUNG ADULT;

EID: 79960842942     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31821705e5     Document Type: Article

References (44)

1. Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ. Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet 1991;38:269-274.
2. Schwartz CE, Dean J, Howard-Peebles PN, et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet 1994;51:400-402. (Pubitemid 24197711)
3. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in fragile X study-preliminary data. Am J Med Genet 1999;83:322-325. (Pubitemid 29162637)
4. Murray A, Webb J, Grimley S, Conway G, Jacobs P. Studies of FRAXA and FRAXE in women with premature ovarian failure. J Med Genet 1998;35: 637-640. (Pubitemid 28371973)
5. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 2008;68:499-509. (Pubitemid 351388699)
6. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905-914. (Pubitemid 121001321)
7. Kronquist KE, Sherman SL, Spector EB. Clinical significance of tri-nucleotide repeats in fragile X testing: a clarification of American College of Medical Genetics guidelines. Genet Med 2008;10:845-847.
8. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8:141-154. (Pubitemid 34428965)
9. Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil Steril 1995;64:740-745.
10. de Bruin JP, Bovenhuis H, van Noord PA, et al. The role of genetic factors in age at natural menopause. Hum Reprod 2001;16:2014-2018. (Pubitemid 32916239)
11. Treloar SA, Do KA, Martin NG. Genetic influences on the age at menopause. Lancet 1998;352:1084-1085. (Pubitemid 28448510)
12. van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde ER. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril 1997;68:95-102. (Pubitemid 27283723)
13. Allen EG, Sullivan AK, Marcus M, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007;22:2142-2152. (Pubitemid 47241859)
14. Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005;20:402-412. (Pubitemid 40277608)
15. Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. Eur J Hum Genet 2006;14:253-255. (Pubitemid 43135871)
16. Tejada MI, Garcia-Alegria E, Bilbao A, et al. Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome. Menopause 2008;15:945-949.
17. Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 2003;72:454-464. (Pubitemid 36194253)
18. Fu YH, Kuhl DP, Pizzuti A, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991;67:1047-1058. (Pubitemid 121001519)
19. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
20. Brown WT, Houck GE Jr, Jeziorowska A, et al. Rapid fragile X carrier screening and prenatal diagnosis using a nonradioactive PCR test. JAMA 1993;270:1569-1575. (Pubitemid 23286720)
21. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979;74:829-836.
22. Do KA, Treloar SA, Pandeya N, et al. Predictive factors of age at menopause in a large Australian twin study. Hum Biol 1998;70:1073-1091. (Pubitemid 28532143)
23. Torgerson DJ, Avenell A, Russell IT, Reid DM. Factors associated with onset of menopause in women aged 45-49. Maturitas 1994;19:83-92. (Pubitemid 24268204)
24. Hunter JE, Epstein MP, Tinker SW, Charen KH, Sherman SL. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet Epidemiol 2008;32:553-559.
25. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
26. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika 1990;77:147-160.
27. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993.
28. Neal MS, Zhu J, Foster WG. Quantification of benzo[a]pyrene and other PAHs in the serum and follicular fluid of smokers versus non-smokers. Reprod Toxicol 2008;25:100-106. (Pubitemid 50009017)
29. Progetto Menopausa Italia Study Group. Premature ovarian failure: frequency and risk factors among women attending a network of menopause clinics in Italy. BJOG 2003;110:59-63.
30. Cramer DW, Xu H, Harlow BL. Does "incessant" ovulation increase risk for early menopause? Am J Obstet Gynecol 1995;172:568-573.
31. de Vries E, den Tonkelaar I, van Noord PA, van der Schouw YT, te Velde ER, Peeters PH. Oral contraceptive use in relation to age at menopause in the DOM cohort. Hum Reprod 2001;16:1657-1662. (Pubitemid 32761746)
32. Stanford JL, Hartge P, Brinton LA, Hoover RN, Brookmeyer R. Factors influencing the age at natural menopause. J Chronic Dis 1987;40:995-1002. (Pubitemid 17153888)
33. Bennett CE, Conway GS, Macpherson JN, Jacobs PA, Murray A. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. Hum Reprod 2010;25:1335-1338.
34. Gleicher N, Weghofer A, Barad DH. Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reprod Biomed Online 2010;20:768-775.
35. Gleicher N, Barad DH. The FMR1 gene as regulator of ovarian recruitment and ovarian reserve. Obstet Gynecol Surv 2010;65:523-530.
36. Bodega B, Bione S, Dalpra L, et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod 2006;21:952-957.
37. Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet 2005;117:376-382. (Pubitemid 41194564)
38. Gleicher N, Weghofer A, Barad DH. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Mullerian hormone. Fertil Steril 2009;91:1700-1706.
39. Gleicher N, Weghofer A, Oktay K, Barad D. Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. Reprod Biomed Online 2009;19:385-390.
40. Rockhill B, Colditz GA, Rosner B. Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol 2000;151:404-408. (Pubitemid 30463618)
41. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005;83:1327-1332. (Pubitemid 40615800)
42. Rohr J, Allen EG, Charen K, et al. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum Reprod 2008;23:1220-1225. (Pubitemid 351757318)
43. Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001;3:359-371.
44. Gleicher N, Weghofer A, Barad DH. Effects of race/ethnicity on triple CGG counts in the FMR1 gene in infertile women and egg donors. Reprod Biomed Online 2010;20:485-491.